Vaccines

Though the product is authorized more than 70 countries, there is currently no reported US trial data, nor application for authorization to the FDA.

The acquisition of the Johnson & Johnson pharmaceutical company's vaccine would likely be completed in the latter half of this year.

A UK health authority representative discussed the possibility of a fall season booster to prevent another winter surge of cases.

The statement comes on the same day as a rare production agreement between pharmaceutical rivals, and Texas' announced lift of spread mitigation measures.

The new trial comes at a time when the FDA has provided guidance on navigating immunogenicity trials for vaccines designed against more transmissible SARS-CoV-2 strains.

A massive assessment of a quickly vaccinated population shows the mRNA vaccine provides greater protection over time.

A talk on optimistic, but pragmatic hopes for HIV cure and vaccine research, led by federal-level experts.

TicoVac will be decided on for both pediatric and adult people at risk of the tick-borne virus in August.

The new advisory is informed by currently-understood effect of authorized vaccines against circulating SARS-CoV-2—which show benefit nonetheless.

The news comes on the same day as new data showing the vaccine's efficacy as a single-dose prophylactic, as well as the company's application for eased storage standards for US supplies.

New South Africa-based data show not only lessened protection versus the region's dominant variant, but a reduced vaccine-induced antibody neutralization.

The two-dose vaccine's ineffective prevention of the more transmissible virus variant led to official seeking better options—and broader outcomes.

Pending advisory committee support and granted authorization, the adenovirus vaccine could become the first single-shot option in the US.

New preliminary phase 3 data show the two-dose vaccine may even hold benefit for single-dose use.

Cohort data shows 87% of infants born to mothers with asymptomatic or symptomatic COVID-19 have developed antibodies at birth.

A video breakdown of the past week's developments and news in leading vaccine candidates.

The to-be-reviewed assessment of real-world vaccine recipients suggests 51% greater efficacy with BNT162b2 after 13-24 days.

The findings accompany news that the company is working on new vaccines to address more transmissible SARS-CoV-2 variants.

After setbacks to its own vaccine candidate, the major drug developer has agreed to aide in production for Europe-bound doses.

In a move being ill-received by clinicians, the COVID-19 vaccine producer is lessening the count of vials being supplied to the government through July.

Current trial evidence is severely lacking for the at-risk group, but does clinical history suggest safety?

An interview on new survey data suggesting a majority of fertility and pregnant patients are not interested in the currently available vaccines.

State and federal officials confirmed Friday that promise for a reserve supply of vaccines meant for second doses is actually unavailable.

In vitro data suggest the more transmissible mutations of the virus are nonetheless prevented by the mRNA vaccine.

In the first week of 2021, the US is currently leading all countries in total vaccine administrations, despite state-level distribution setbacks.

The newly published data show no patient given the two-dose mRNA vaccine has yet to report a case of severe COVID-19.

The agreement could mean upwards of 70 million more doses for eligible patients in mid-2021.

Up to 40% more doses—or, enough to vaccinate another person with two doses—has been observed in the vials distributed at the beginning of this week.

The country's first authorized vaccine will be first available to healthcare workers and long-term care residents.

The VRBPAC committee voted 17-4, with 1 abstention, to support the benefit-risk profile of BNT162b2 for preventing COVID-19 in persons aged 16 years and older.